Published in Lancet on July 27, 2002
Membrane vesicles as conveyors of immune responses. Nat Rev Immunol (2009) 14.72
Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol (2013) 10.02
Cells release prions in association with exosomes. Proc Natl Acad Sci U S A (2004) 5.17
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature (2015) 5.15
Regulation of immune responses by extracellular vesicles. Nat Rev Immunol (2014) 3.24
Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One (2010) 3.23
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One (2009) 3.10
Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med (2011) 3.03
Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem (2009) 2.99
Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer (2010) 2.95
Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology (2011) 2.90
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Exosomes: immune properties and potential clinical implementations. Semin Immunopathol (2010) 2.60
Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res (2008) 2.41
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med (2005) 2.26
Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer (2005) 2.17
Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med (2009) 2.14
Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol (2004) 2.13
Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) (2013) 2.12
Proteomic and immunologic analyses of brain tumor exosomes. FASEB J (2008) 2.11
Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med (2011) 2.10
Microvesicles and viral infection. J Virol (2011) 2.10
Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol Cell Proteomics (2009) 2.08
Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics (2010) 2.04
Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia (2006) 1.98
Cell to cell signalling via exosomes through esRNA. Cell Adh Migr (2007) 1.95
Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS One (2010) 1.94
Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One (2010) 1.94
Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol (2011) 1.93
A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J (2006) 1.92
Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics (2009) 1.84
Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res (2011) 1.83
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol (2011) 1.67
Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med (2006) 1.63
Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One (2008) 1.63
Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip (2009) 1.61
Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res (2012) 1.60
Tetraspanins in extracellular vesicle formation and function. Front Immunol (2014) 1.56
Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol (2013) 1.54
The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J (2007) 1.50
Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front Physiol (2012) 1.49
Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer (2009) 1.44
Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One (2012) 1.43
Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem (2012) 1.40
Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ (2013) 1.39
Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front Immunol (2015) 1.37
Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica (2011) 1.37
Targeting stroma to treat cancers. Semin Cancer Biol (2011) 1.33
Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med (2010) 1.32
Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles (2015) 1.30
Role of exosomes in immune regulation. J Cell Mol Med (2006) 1.29
Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One (2011) 1.28
Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem (2008) 1.27
Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. Mol Cell Proteomics (2012) 1.26
Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck (2009) 1.25
Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol (2013) 1.22
Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem (2013) 1.22
Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells (2014) 1.20
Ectosomes as modulators of inflammation and immunity. Clin Exp Immunol (2010) 1.19
Whole tumor antigen vaccines. Semin Immunol (2010) 1.19
The application of exosomes as a nanoscale cancer vaccine. Int J Nanomedicine (2010) 1.18
Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ (2014) 1.18
Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology (2006) 1.16
More insights into the immunosuppressive potential of tumor exosomes. J Transl Med (2008) 1.14
Exosomes and immune surveillance of neoplastic lesions: a review. Biotech Histochem (2012) 1.12
Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model. PLoS One (2011) 1.11
Exosomes in tumour immunity. Curr Oncol (2009) 1.10
Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic? Proteomics (2014) 1.09
Personalized dendritic cell-based tumor immunotherapy. Immunotherapy (2010) 1.08
Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc Natl Acad Sci U S A (2013) 1.04
The biology and function of exosomes in cancer. J Clin Invest (2016) 1.04
Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog (2013) 1.04
Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology (2013) 1.03
Tumor-derived exosomes in oncogenic reprogramming and cancer progression. Cell Mol Life Sci (2014) 1.02
Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin. PLoS One (2014) 1.02
Exosome in tumour microenvironment: overview of the crosstalk between normal and cancer cells. Biomed Res Int (2014) 1.01
Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies. Br J Pharmacol (2014) 1.01
Extracellular vesicles as emerging intercellular communicasomes. BMB Rep (2014) 1.00
Label-free quantitative detection of tumor-derived exosomes through surface plasmon resonance imaging. Anal Chem (2014) 0.99
DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Res (2010) 0.99
Extracellular vesicles: communication, coercion, and conditioning. Mol Biol Cell (2013) 0.99
Tumor-derived exosomes: A message delivery system for tumor progression. Commun Integr Biol (2014) 0.99
Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol (2013) 0.99
Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J Cell Mol Med (2010) 0.98
Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J Extracell Vesicles (2013) 0.97
Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One (2014) 0.97
Quantitative nanostructural and single-molecule force spectroscopy biomolecular analysis of human-saliva-derived exosomes. Langmuir (2011) 0.96
Detection of tumor cell-specific mRNA and protein in exosome-like microvesicles from blood and saliva. PLoS One (2014) 0.95
Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol (2013) 0.95
Immunotherapeutic potential of extracellular vesicles. Front Immunol (2014) 0.94
Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget (2015) 0.94
Plasma-derived MHC class II+ exosomes from tumor-bearing mice suppress tumor antigen-specific immune responses. Eur J Immunol (2012) 0.93
Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling. PLoS One (2012) 0.93
Versatile roles of extracellular vesicles in cancer. J Clin Invest (2016) 0.92
The exosomes in tumor immunity. Oncoimmunology (2015) 0.92
Emerging roles for extracellular vesicles in tissue engineering and regenerative medicine. Tissue Eng Part B Rev (2014) 0.92
Estrogen regulates vesicle trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells. Int J Clin Exp Pathol (2009) 0.91
Biomolecular characterization of exosomes released from cancer stem cells: Possible implications for biomarker and treatment of cancer. Oncotarget (2015) 0.91
The water channel aquaporin-1 partitions into exosomes during reticulocyte maturation: implication for the regulation of cell volume. Blood (2009) 0.90
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol (2006) 13.29
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Renal cell carcinoma. Lancet (2009) 6.92
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol (2009) 5.44
NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell (2006) 5.35
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature (2003) 4.18
Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 3.95
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol (2002) 3.78
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Non-small-cell lung cancer. Lancet (2011) 3.45
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2013) 3.31
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol (2004) 3.25
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol (2012) 3.18
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity (2008) 2.98
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med (2007) 2.89
Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity (2009) 2.86
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res (2006) 2.84
ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol (2009) 2.82
Lipid raft-associated protein sorting in exosomes. Blood (2003) 2.76
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70
Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat Cell Biol (2007) 2.69
Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination. Immunity (2006) 2.66
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol (2009) 2.50
Phagocytosis and antigen presentation in dendritic cells. Immunol Rev (2007) 2.49
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA (2004) 2.47
The IKK complex contributes to the induction of autophagy. EMBO J (2009) 2.41
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood (2005) 2.34
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med (2005) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26
Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity (2013) 2.23
Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol (2008) 2.23